Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.

Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, Nguyen QD, Craig JW, Morgan EA, Vega F, Aster JC, Sarosiek KA, Shalek AK, Hemann MT, Weinstock DM.

Cancer Discov. 2019 Jul;9(7):944-961. doi: 10.1158/2159-8290.CD-18-1393. Epub 2019 Apr 30.

PMID:
31040105
2.

T Cells and Regulated Cell Death: Kill or Be Killed.

Spetz J, Presser AG, Sarosiek KA.

Int Rev Cell Mol Biol. 2019;342:27-71. doi: 10.1016/bs.ircmb.2018.07.004. Epub 2018 Aug 29.

PMID:
30635093
3.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
4.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.

McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr.

Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13.

PMID:
30220459
5.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

6.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S.

Cancer Lett. 2017 Jun 1;395:1-10. doi: 10.1016/j.canlet.2017.02.028. Epub 2017 Mar 1.

PMID:
28259821
7.

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A.

Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22.

8.

Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.

Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SWG, Gautier F, Juin PP.

Cell Rep. 2016 Dec 20;17(12):3347-3358. doi: 10.1016/j.celrep.2016.11.064.

9.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.

Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.

10.

Interleukin 21 - its potential role in the therapy of B-cell lymphomas.

Bhatt S, Sarosiek KA, Lossos IS.

Leuk Lymphoma. 2017 Jan;58(1):17-29. Epub 2016 Jul 13. Review.

PMID:
27405876
11.
12.

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.

Blood. 2015 Sep 24;126(13):1555-64. doi: 10.1182/blood-2015-01-624585. Epub 2015 Jul 20.

13.

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.

Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.

14.

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.

15.

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.

Cancer Res. 2014 Jun 1;74(11):3146-56. doi: 10.1158/0008-5472.CAN-13-3728. Epub 2014 Mar 27.

16.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

17.

BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A.

Mol Cell. 2013 Sep 26;51(6):751-65. doi: 10.1016/j.molcel.2013.08.048.

18.

Mitochondria: gatekeepers of response to chemotherapy.

Sarosiek KA, Ni Chonghaile T, Letai A.

Trends Cell Biol. 2013 Dec;23(12):612-9. doi: 10.1016/j.tcb.2013.08.003. Epub 2013 Sep 21. Review.

19.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.

Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.

20.

HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway.

Jiang X, Lu X, McNamara G, Liu X, Cubedo E, Sarosiek KA, Sánchez-García I, Helfman DM, Lossos IS.

Blood. 2010 Dec 9;116(24):5217-27. doi: 10.1182/blood-2010-04-281568. Epub 2010 Sep 15.

21.

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13069-74. doi: 10.1073/pnas.1002985107. Epub 2010 Jul 6.

22.

Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.

Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS.

Blood. 2010 Jan 21;115(3):570-80. doi: 10.1182/blood-2009-08-239996. Epub 2009 Nov 20.

23.

Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS.

Br J Haematol. 2009 Nov;147(3):308-18. doi: 10.1111/j.1365-2141.2009.07851.x. Epub 2009 Aug 19.

24.

Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.

Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, Tibshirani R, Lossos IS.

Blood. 2009 Apr 16;113(16):3754-64. doi: 10.1182/blood-2008-10-184077. Epub 2008 Dec 1.

25.

PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.

Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS.

Blood. 2008 Nov 15;112(10):4098-108. doi: 10.1182/blood-2008-03-148726. Epub 2008 Aug 20.

26.

T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.

Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS.

Mol Cell Biol. 2007 Mar;27(6):2166-79. Epub 2007 Jan 8.

Supplemental Content

Loading ...
Support Center